Amicus Therapeutics Company Profile (NASDAQ:FOLD)

About Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics logoAmicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:FOLD
  • CUSIP: 03152W10
  • Web:
  • Market Cap: $2.3 billion
  • Outstanding Shares: 164,566,000
Average Prices:
  • 50 Day Moving Avg: $13.24
  • 200 Day Moving Avg: $9.90
  • 52 Week Range: $4.41 - $14.36
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.34
  • P/E Growth: -0.18
Sales & Book Value:
  • Annual Revenue: $16.28 million
  • Price / Sales: 141.11
  • Book Value: $1.86 per share
  • Price / Book: 7.51
  • EBIDTA: ($186,930,000.00)
  • Net Margins: -1,279.88%
  • Return on Equity: -61.25%
  • Return on Assets: -20.08%
  • Debt-to-Equity Ratio: 0.60%
  • Current Ratio: 2.39%
  • Quick Ratio: 2.35%
  • Average Volume: 3.96 million shs.
  • Beta: 1.82
  • Short Ratio: 6.74

Frequently Asked Questions for Amicus Therapeutics (NASDAQ:FOLD)

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings results on Monday, August, 7th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.03. The business had revenue of $7.16 million for the quarter, compared to analysts' expectations of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same period in the previous year, the company posted ($0.40) EPS. View Amicus Therapeutics' Earnings History.

When will Amicus Therapeutics make its next earnings announcement?

Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Amicus Therapeutics.

Where is Amicus Therapeutics' stock going? Where will Amicus Therapeutics' stock price be in 2017?

6 brokerages have issued 1-year price targets for Amicus Therapeutics' shares. Their forecasts range from $9.00 to $18.00. On average, they anticipate Amicus Therapeutics' share price to reach $15.08 in the next year. View Analyst Ratings for Amicus Therapeutics.

What are analysts saying about Amicus Therapeutics stock?

Here are some recent quotes from research analysts about Amicus Therapeutics stock:

  • 1. According to Zacks Investment Research, "AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. " (7/19/2017)
  • 2. Cowen and Company analysts commented, "This morning, FOLD announced that after more recent FDA talks and written." (7/11/2017)

Are investors shorting Amicus Therapeutics?

Amicus Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 33,782,444 shares, an increase of 1.2% from the August 15th total of 33,370,329 shares. Based on an average daily trading volume, of 2,769,628 shares, the short-interest ratio is currently 12.2 days. Currently, 21.2% of the shares of the stock are short sold.

Who are some of Amicus Therapeutics' key competitors?

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the folowing people:

  • John F. Crowley J.D., Chairman of the Board, Chief Executive Officer
  • Bradley L. Campbell, President, Chief Operating Officer
  • William D. Baird III, Chief Financial Officer
  • Daphne E. Quimi, Senior Vice President - Finance and Administration, Corporate Controller
  • Kurt J. W. Andrews, Senior Vice President - Human Resources
  • Hung Viet Do, Chief Scientific Officer
  • Ellen S. Rosenberg, General Counsel and Corporate Secretary
  • Jay A. Barth M.D., Chief Medical Officer
  • Donald J. Hayden Jr., Lead Independent Director
  • Robert A. Essner, Independent Director

Who owns Amicus Therapeutics stock?

Amicus Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Redmile Group LLC (7.32%), BlackRock Inc. (8.24%), Vanguard Group Inc. (6.38%), Jennison Associates LLC (6.25%) and Palo Alto Investors LLC (4.83%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, Kenneth Peist, Life Sciences Maste Perceptive, Margaret G Mcglynn, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.

Who sold Amicus Therapeutics stock? Who is selling Amicus Therapeutics stock?

Amicus Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Grosvenor Capital Management L.P., Canada Pension Plan Investment Board, AXA, Sectoral Asset Management Inc, Victory Capital Management Inc., Tekla Capital Management LLC, Asymmetry Capital Management L.P. and BlackRock Inc.. Company insiders that have sold Amicus Therapeutics stock in the last year include Bradley L Campbell, Daphne Quimi, Hung Do, Jay Barth and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.

Who bought Amicus Therapeutics stock? Who is buying Amicus Therapeutics stock?

Amicus Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Farallon Capital Management LLC, FMR LLC, Redmile Group LLC, Vanguard Group Inc., Balyasny Asset Management LLC, Emory University and Quantitative Investment Management LLC. Company insiders that have bought Amicus Therapeutics stock in the last two years include Ellen Rosenberg, Life Sciences Maste Perceptive, Margaret G Mcglynn and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.

How do I buy Amicus Therapeutics stock?

Shares of Amicus Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amicus Therapeutics' stock price today?

One share of Amicus Therapeutics stock can currently be purchased for approximately $13.96.

MarketBeat Community Rating for Amicus Therapeutics (NASDAQ FOLD)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  363
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Amicus Therapeutics (NASDAQ:FOLD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.08 (8.05% upside)

Analysts' Ratings History for Amicus Therapeutics (NASDAQ:FOLD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/16/2017Leerink SwannReiterated RatingOutperform$18.00 -> $17.00LowView Rating Details
9/14/2017Cowen and CompanyReiterated RatingOutperform$16.00 -> $18.00LowView Rating Details
9/13/2017Chardan CapitalReiterated RatingBuy -> Buy$17.50 -> $16.50LowView Rating Details
8/9/2017J P Morgan Chase & CoReiterated RatingOverweight$13.00 -> $15.00HighView Rating Details
7/12/2017Robert W. BairdBoost Price TargetOutperform$12.00 -> $15.00MediumView Rating Details
5/25/2017Bank of America CorporationLower Price TargetBuy$10.00 -> $9.00MediumView Rating Details
3/30/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$10.00N/AView Rating Details
3/8/2016Janney Montgomery ScottUpgradeNeutral -> Buy$10.00 -> $12.00N/AView Rating Details
(Data available from 9/20/2015 forward)


Earnings History for Amicus Therapeutics (NASDAQ:FOLD)
Earnings by Quarter for Amicus Therapeutics (NASDAQ:FOLD)
Earnings History by Quarter for Amicus Therapeutics (NASDAQ FOLD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.37)N/AView Earnings Details
8/7/2017Q2 2017($0.37)($0.34)$6.96 million$7.16 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.37)($0.39)$4.16 million$4.20 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.33)($0.32)$3.16 million$2.83 millionViewListenView Earnings Details
11/7/2016Q3($0.31)($0.33)$1.71 million$2.10 millionViewListenView Earnings Details
8/9/2016Q2($0.33)($0.40)$0.17 millionViewN/AView Earnings Details
5/3/2016Q1($0.34)($0.35)ViewListenView Earnings Details
11/3/2015Q3($0.25)($0.32)ViewN/AView Earnings Details
8/5/2015Q215($0.24)($0.26)ViewN/AView Earnings Details
5/5/2015Q115($0.14)($0.25)$0.50 millionViewN/AView Earnings Details
3/3/2015Q414($0.18)($0.24)$0.48 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.21)($0.22)$1.00 million$0.29 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.24)($0.23)$0.48 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.23)($0.25)$0.20 million$0.46 millionViewN/AView Earnings Details
3/3/2014Q4 13($0.32)($0.22)$0.32 millionViewN/AView Earnings Details
11/11/2013Q3($0.32)($0.29)ViewN/AView Earnings Details
8/7/2013Q2 2013($0.35)($0.31)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.30)($0.34)ViewN/AView Earnings Details
11/5/2012Q312($0.24)($0.31)$8.82 million$5.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amicus Therapeutics (NASDAQ:FOLD)
2017 EPS Consensus Estimate: ($1.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.39)($0.39)($0.39)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.30)($0.30)($0.30)
Q4 20171($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)


Dividend History for Amicus Therapeutics (NASDAQ:FOLD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Amicus Therapeutics (NASDAQ:FOLD)
Insider Ownership Percentage: 3.40%
Insider Trades by Quarter for Amicus Therapeutics (NASDAQ:FOLD)
Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)
Insider Trades by Quarter for Amicus Therapeutics (NASDAQ:FOLD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/13/2017Life Sciences Maste PerceptiveMajor ShareholderBuy1,500,000$12.25$18,375,000.00View SEC Filing  
6/19/2017Jay BarthInsiderSell30,000$10.00$300,000.00View SEC Filing  
5/19/2017Hung DoInsiderSell29,914$8.00$239,312.00View SEC Filing  
3/2/2017Bradley L CampbellCOOSell49,050$8.00$392,400.00View SEC Filing  
1/13/2017Hung DoInsiderSell25,000$6.00$150,000.00View SEC Filing  
12/30/2016Perceptive Advisors LlcMajor ShareholderBuy94,750$4.96$469,960.00View SEC Filing  
12/29/2016Perceptive Advisors LlcMajor ShareholderBuy142,125$4.87$692,148.75View SEC Filing  
12/23/2016Perceptive Advisors LlcMajor ShareholderBuy85,275$4.81$410,172.75View SEC Filing  
12/22/2016Perceptive Advisors LlcMajor ShareholderBuy189,500$4.51$854,645.00View SEC Filing  
11/9/2016Daphne QuimiSVPSell8,546$8.00$68,368.00View SEC Filing  
11/1/2016Hung DoInsiderSell25,000$7.00$175,000.00View SEC Filing  
10/3/2016Hung DoInsiderSell25,000$7.25$181,250.00View SEC Filing  
9/20/2016William D Baird IIICFOSell20,500$8.00$164,000.00View SEC Filing  
9/6/2016Hung DoInsiderSell25,000$7.00$175,000.00View SEC Filing  
8/25/2016Perceptive Advisors LlcInsiderSell1,100,000$6.81$7,491,000.00View SEC Filing  
8/4/2016Jay BarthInsiderSell10,458$7.00$73,206.00View SEC Filing  
7/27/2016Jay BarthInsiderSell20,916$7.00$146,412.00View SEC Filing  
6/2/2016Ellen RosenbergGeneral CounselBuy15,000$7.67$115,050.00View SEC Filing  
11/10/2015Margaret G McglynnDirectorBuy10,000$10.27$102,700.00View SEC Filing  
10/7/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.27$313,500.00View SEC Filing  
10/6/2015Perceptive Advisors LlcMajor ShareholderBuy750,000$6.71$5,032,500.00View SEC Filing  
10/1/2015Kenneth PeistVPSell10,000$13.14$131,400.00View SEC Filing  
9/21/2015Bradley L. CampbellCOOSell13,001$16.78$218,156.78View SEC Filing  
9/21/2015William D. Baird IIICFOSell15,236$16.78$255,660.08View SEC Filing  
9/15/2015Hung DoInsiderSell25,000$17.75$443,750.00View SEC Filing  
9/14/2015Daphne QuimiVPSell2,500$18.08$45,200.00View SEC Filing  
7/16/2015John F CrowleyCEOSell16,025$16.00$256,400.00View SEC Filing  
7/14/2015John F CrowleyCEOSell142,250$15.03$2,138,017.50View SEC Filing  
7/13/2015Glenn SblendorioDirectorSell10,000$15.00$150,000.00View SEC Filing  
7/13/2015John F CrowleyCEOSell7,750$15.01$116,327.50View SEC Filing  
7/13/2015Ken ValenzanoSVPSell15,000$15.00$225,000.00View SEC Filing  
7/8/2015Dipal DoshiSVPSell6,250$13.87$86,687.50View SEC Filing  
7/1/2015Jayne GershkowitzSVPSell10,649$13.97$148,766.53View SEC Filing  
7/1/2015Kenneth PeistVPSell10,000$13.98$139,800.00View SEC Filing  
6/23/2015Donald J Hayden JrDirectorSell55,000$14.01$770,550.00View SEC Filing  
6/22/2015Jeff CastelliSVPSell18,981$13.94$264,595.14View SEC Filing  
6/19/2015Bradley L CampbellCOOSell13,000$13.26$172,380.00View SEC Filing  
6/19/2015Enrique DiloneSVPSell14,045$13.26$186,236.70View SEC Filing  
6/19/2015William D Baird IIICFOSell15,235$13.26$202,016.10View SEC Filing  
6/15/2015Jeff CastelliSVPSell7,377$14.17$104,532.09View SEC Filing  
6/15/2015Julie YuVPSell8,195$14.17$116,123.15View SEC Filing  
6/8/2015Jeff CastelliSVPSell17,312$12.87$222,805.44View SEC Filing  
6/8/2015John F CrowleyCEOSell55,000$13.01$715,550.00View SEC Filing  
5/11/2015Jeff CastelliSVPSell10,000$10.84$108,400.00View SEC Filing  
5/11/2015Kenneth PeistVPSell12,500$10.84$135,500.00View SEC Filing  
5/11/2015William D Baird IIICFOSell24,800$10.84$268,832.00View SEC Filing  
4/15/2015Glenn SblendorioDirectorSell20,000$12.50$250,000.00View SEC Filing  
4/15/2015Ken ValenzanoVPSell5,000$12.50$62,500.00View SEC Filing  
4/10/2015John F CrowleyCEOSell11,678$12.00$140,136.00View SEC Filing  
4/1/2015Jeff CastelliVPSell9,489$10.69$101,437.41View SEC Filing  
1/5/2015Jeff CastelliVPSell4,667$9.00$42,003.00View SEC Filing  
12/4/2014John F CrowleyCEOSell89,000$8.36$744,040.00View SEC Filing  
11/25/2014Bradley L CampbellCOOSell7,250$8.00$58,000.00View SEC Filing  
11/25/2014Jeff CastelliVPSell8,103$8.00$64,824.00View SEC Filing  
11/25/2014William D Baird IIICFOSell10,000$8.00$80,000.00View SEC Filing  
11/19/2014Perceptive Advisors LlcMajor ShareholderBuy2,100,000$6.50$13,650,000.00View SEC Filing  
10/27/2014Plc GlaxosmithklineMajor ShareholderSell11,315,825$5.29$59,860,714.25View SEC Filing  
10/3/2014Jeff CastelliVPSell8,552$7.00$59,864.00View SEC Filing  
10/3/2014William D Baird IIICFOSell10,000$7.00$70,000.00View SEC Filing  
10/2/2014Julie YuVPSell4,759$5.99$28,506.41View SEC Filing  
9/29/2014Daphne QuimiVPSell10,738$6.10$65,501.80View SEC Filing  
9/29/2014William D Baird IIICFOSell25,311$6.09$154,143.99View SEC Filing  
8/27/2014Glenn SblendorioDirectorSell10,000$6.50$65,000.00View SEC Filing  
8/27/2014Jayne GershkowitzVPSell5,000$7.00$35,000.00View SEC Filing  
8/25/2014Bradley L CampbellCOOSell7,000$6.00$42,000.00View SEC Filing  
8/25/2014Jayne GershkowitzVPSell5,000$6.00$30,000.00View SEC Filing  
8/20/2014Bradley L CampbellCOOSell18,750$5.40$101,250.00View SEC Filing  
8/20/2014Enrique DiloneVPSell12,810$5.40$69,174.00View SEC Filing  
6/30/2014Perceptive Advisors LlcMajor ShareholderBuy4,000,000$3.50$14,000,000.00View SEC Filing  
11/20/2013Plc Glaxosmithklinemajor shareholderBuy1,500,000$2.00$3,000,000.00View SEC Filing  
3/15/2013Sol J BarerDirectorBuy25,000$3.40$85,000.00View SEC Filing  
11/13/2012Joan WinterbottomSVPBuy1,665$4.54$7,559.10View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Amicus Therapeutics (NASDAQ:FOLD)
Latest Headlines for Amicus Therapeutics (NASDAQ:FOLD)
DateHeadline logoAmicus Therapeutics (FOLD) Granted Fast Track Designation for Migalastat for Treatment of Fabry Disease - September 19 at 6:45 PM logoU.S. FDA Grants Fast Track Designation for Amicus Therapeutics’ Migalastat for Treatment of Fabry Disease - September 19 at 6:45 PM logo[$$] Clinical Development News, Sept. 11-15 - September 18 at 4:05 AM logoAmicus Therapeutics (FOLD) Reports Health Canada Approval for Galafold for Treatment of Fabry Disease - September 16 at 6:08 PM logoAmicus Therapeutics, Inc. (FOLD) Stock Rating Reaffirmed by Leerink Swann - September 16 at 9:50 AM logoLeerink Swann Comments on Amicus Therapeutics, Inc.'s Q3 2017 Earnings (FOLD) - September 15 at 8:02 AM logoAmicus Therapeutics Announces Approval for Galafold™ (Migalastat) for Treatment of Fabry Disease in Canada - September 14 at 7:23 PM logoCowen and Company Reiterates "Outperform" Rating for Amicus Therapeutics, Inc. (FOLD) - September 14 at 1:04 PM logoAmicus: Phase 3 SD-101 Study Fails To Meet Primary Endpoints - Quick Facts - September 13 at 8:15 PM logoAmicus Therapeutics Announces Top-Line Phase 3 Results for SD-101 in Epidermolysis Bullosa - September 13 at 8:15 PM logoA father's fight to find a cure for his children's rare disease - September 13 at 8:15 PM logoAmicus abandons wound treatment, focus shifts to future trial data - September 13 at 8:15 PM logoAmicus Therapeutics, Inc. (FOLD) Price Target Cut to $16.50 by Analysts at Chardan Capital - September 13 at 5:30 PM logoAmicus Therapeutics' SD-101 flunks late-stage study in epidermolysis bullosa; shares down 13% premarket - September 13 at 7:31 AM logoZacks: Brokerages Anticipate Amicus Therapeutics, Inc. (FOLD) Will Announce Quarterly Sales of $9.93 Million - September 13 at 5:52 AM logoOptions Traders Expect Huge Moves in Amicus Therapeutics (FOLD) Stock - Nasdaq - September 13 at 5:39 AM logoOptions Traders Expect Huge Moves in Amicus Therapeutics (FOLD) Stock - September 12 at 7:35 PM logoIs Amicus Therapeutics Stock Still a Strong Buy? - September 10 at 8:37 AM logoCritical Contrast: Amicus Therapeutics (FOLD) versus its Peers - September 9 at 10:32 PM logoTime to Bring Amicus Therapeutics Into the 'FOLD' - September 8 at 7:12 PM logoAmicus Therapeutics, Inc. (FOLD) Given Consensus Rating of "Buy" by Brokerages - September 2 at 4:40 AM logo Brokerages Expect Amicus Therapeutics, Inc. (FOLD) Will Post Quarterly Sales of $9.93 Million - August 26 at 6:48 PM logoAmicus Therapeutics to Highlight Fabry Disease Program at the 13th International Congress of Inborn Errors of ... - GlobeNewswire (press release) - August 26 at 1:25 AM logoAmicus Therapeutics to Highlight Fabry Disease Program at the 13th International Congress of Inborn Errors of Metabolism (ICIEM) - August 26 at 1:25 AM logo Analysts Expect Amicus Therapeutics, Inc. (FOLD) Will Post Earnings of -$0.39 Per Share - August 24 at 2:06 AM logoToday's Research Reports on Stocks to Watch: Amicus Therapeutics Inc. and Ritter Pharmaceuticals Inc. - August 21 at 6:13 PM logo[$$] Clinical Development News, Aug. 14-18 - August 20 at 10:22 PM logoAmicus Therapeutics, Inc. (FOLD) Stock Rating Upgraded by BidaskClub - August 20 at 1:14 PM logoUpcoming Events - Late-Stage Data Due For Amicus And Insmed - Seeking Alpha - August 18 at 6:39 PM logoAmicus Therapeutics (FOLD) Receives Approval for Galafold for ... - - August 17 at 4:53 AM logoAmicus Therapeutics (FOLD) Receives Approval for Galafold for Treatment of Fabry Disease in Australia - August 16 at 5:28 AM logoAmicus Therapeutics Announces Approval for Galafold™ (Migalastat) for Treatment of Fabry Disease in Australia - August 15 at 7:24 PM logoCowen and Company Reiterates Buy Rating for Amicus Therapeutics, Inc. (NASDAQ:FOLD) - August 14 at 4:18 PM logoAmicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Rating Lowered by BidaskClub - August 13 at 11:58 AM logoAmicus Therapeutics, Inc. (NASDAQ:FOLD) Short Interest Down 4.4% in July - August 12 at 3:08 AM logoAmicus Therapeutics Sees Unusually Large Options Volume (NASDAQ:FOLD) - August 10 at 8:06 AM logoAmicus Therapeutics, Inc. (FOLD) Earns Overweight Rating from J P Morgan Chase & Co - August 10 at 12:58 AM logoThe Sole Reason Amicus Therapeutics, Inc. Exploded 29% Higher in July - Motley Fool - August 9 at 6:55 PM logoThe Sole Reason Amicus Therapeutics, Inc. Exploded 29% Higher in July - August 9 at 3:35 PM logoQ3 2017 EPS Estimates for Amicus Therapeutics, Inc. Lifted by Leerink Swann (NASDAQ:FOLD) - August 9 at 8:08 AM logoAmicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Buy" by Brokerages - August 8 at 7:46 AM logoEdited Transcript of FOLD earnings conference call or presentation 7-Aug-17 12:30pm GMT - August 7 at 9:15 PM logoAmicus Therapeutics' (FOLD) CEO John Crowley on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 7 at 4:15 PM logoAmicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates - August 7 at 4:15 PM logoAmicus Therapeutics reports 2Q loss - August 7 at 4:15 PM logoAmicus Therapeutics, Inc. (NASDAQ:FOLD) Posts Earnings Results, Beats Estimates By $0.02 EPS - August 7 at 8:50 AM logo$6.96 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter - August 7 at 8:32 AM logoAmicus Therapeutics, Inc. (NASDAQ:FOLD) to Release Quarterly Earnings on Monday - July 31 at 8:05 AM logoContrasting Amicus Therapeutics (NASDAQ:FOLD) & Eli Lilly and (LLY) - July 27 at 9:34 AM logoShort Interest in Amicus Therapeutics, Inc. (FOLD) Rises By 3.8% - July 27 at 7:06 AM



Amicus Therapeutics (FOLD) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff